ClinicalTrials.gg
RecruitingNCT06132178PSILOBSDUpdated Nov 26, 2025

Psilocybin rTMS for Treatment Resistant Depression

A Phase 2 interventional study of Psilocybin and Accelerated intermittent theta burst (aiTBS) rTMS treatment in Treatment Resistant Depression, MDD and Major Depressive Disorder, sponsored by University of Texas at Austin. Recruiting at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by University of Texas at Austin · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
22 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant — 9 open to participants now, 14 under way, 2 of them phase 3. Psilocybin · Depressive Disorder, Treatment-Resistant.

Planned enrollment
6th of 25
100 · median 30
Started
2025
with 2 others
Phase 2
18 of 25
8 open now
Primary completion
2029-12
later than 11 of 13 live
Registered
13th of 25
by date

Among the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 11 of the 13 other live ones, and was the 13th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 22 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing psilocybin in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

Read the detailed description

This will be a phase II 2x2 design (device and dose) clinical trial. 100 participants, ages 22-76, with treatment-resistant MDD will be randomized to treatment with either: a) 25mg of COMP360 (N=50); or b) 1mg of COMP360 (low-dose comparator; N=50) with appropriate psychological preparation, support, and integration sessions with trained therapists. This will then be directly followed by one of two subsequent treatment conditions: i) the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold50,51; or ii) sham iTBS delivered in the same fashion. Individuals will undergo screening, a baseline clinical assessment and neurobiological assessment of functional magnetic resonance imaging (fMRI) and electroencephalographic (EEG) recordings. Individuals will then return on a subsequent day to begin the course of psilocybin therapy. Preparation sessions will occur on the first two out of five days (\~1.5-2 hrs each day), psilocybin dosing will occur on the third day (\~6-8 hours), integration session (\~1 hour) and post-dosing assessments will occur on the fourth day, and a final integration session (\~1 hour) and post-psilocybin clinical and neurobiological assessments will occur on the last of the five days. The following week, the individual will return to the lab to begin the course of active or sham SNT, for 10 hrs. a day (10 min once per 60 min, 50-minute inter-session interval, repeated 10 times daily) for 5 days. This is the protocol now FDA-cleared for treatment of treatment-resistant MDD, known as Stanford Neuromodulation Therapy and commercialized by Magnus Medical (see support letter from Magus Medical). In the third week, the individual will return to complete post-SNT clinical assessments and to complete a post-SNT neurobiological (fMRI and EEG) assessment. Individuals will complete long-term follow-up clinical assessments at 1 month, 2 months, 3 months, 4 months, 6 months, 9 months, and 12 months post-initiation of first treatment (psilocybin administration) to assess durability of clinical response and identify potential points of depression relapse over a sustained period of time.

Aims:

To determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

To determine if the combination of psilocybin therapy followed by SAINT demonstrates superior efficacy relative to either treatment alone acutely (primary acute endpoint will be \~14 days after the initiation of the treatment sequence) and over time (additional endpoints at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, and 12 months following cessation of the treatment protocol).

To determine the neurobiological changes following the combination treatment (assessment points at baseline, 2 days post-psilocybin, and \~14 days post-psilocybin/2-4 days post cessation of accelerated theta burst), and if the magnitude or nature of such changes are different from those demonstrated in either treatment alone.

Investigate how psychedelic treatment may impact blood biomarkers of inflammation (e.g., inflammatory cytokines) and how select functional genetic polymorphisms may moderate the effect of the psychedelic treatment on subsequent functional brain changes.

03

Conditions studied

  • Treatment Resistant Depression
  • MDD
  • Major Depressive Disorder
  • Recurrent Depression
  • Depression
04

Who can participate

Ages eligible
22 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults, ages 22-65.
  2. English language comprehension suitable to understand experimenter instructions and to communicate to study personnel/staff reasonably easily.
  3. Current major depressive episode (without psychotic features), either as part of recurrent major depressive disorder (MDD) or single episode MDD with current episode present for at least the past 3 months (as determined by the Structured Clinical Interview for ; SCID-5).
  4. Montgomery Asberg Depression Rating Scale (MADRS) score of 20 or greater at baseline assessment (at least moderate severity).
  5. 1. Treatment-resistant MDD, defined as either: a) failure to respond to an adequate dose and duration of two or more pharmacological treatments, with at least one failed medication trial occurring in the current major depressive episode; or b) failure to respond to an adequate dose and duration of 2 or more pharmacological treatments of different pharmacological classes in one or more past major depressive episodes. Adequate treatment dose and duration will be determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ). Augmentation, where an add-on medication is used, will be counted as a second treatment, provided it is approved as an adjunctive treatment of MDD in the country where prescribed.
  6. Willingness and ability to attend daily, full-day visits to the research site for a period of \~2 weeks and to participate in all study procedures (clinical assessments, treatments, and neurobiological assessments).
  7. If currently taking an antidepressant medication (an SSRI, SNRI, or atypical antidepressant), antipsychotic, and/or other augmenting medication (e.g., lithium), willingness to discontinue medication(s) over a 2-8 week period with the assistance of study staff and maintain at least a 2-5 week period (5-week period for fluoxetine) off of medications prior to the baseline visit AND willingness to remain off medications for a period of 1 month following the end of the treatment course (approximately 6-8 weeks after the baseline visit).

Exclusion criteria

Exclusion Criteria:

  1. Prior history or current diagnosis of a psychotic disorder (including MDD with psychotic features), bipolar disorder, or personality disorder (based on medical history, clinician judgement, SCID-5 and/or SCID for Personality Disorders).
  2. Current diagnosis of posttraumatic stress disorder, acute stress disorder, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, or alcohol or substance-use disorder.
  3. Having met criteria for an alcohol or substance-use disorder within the past year.
  4. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current major depressive episode.
  5. Any prior rTMS treatment (10Hz, 5Hz, 1Hz, or conventional intermittent theta burst).
  6. Current participation in an evidence-based psychotherapy for major depression (e.g., cognitive behavioral therapy, behavioral activation). Ongoing supportive psychotherapy is allowable if maintained at the same frequency throughout the duration of the short-term follow-up clinical endpoint (1 month after treatment cessation) of the study and if no recent change in therapy type or frequency for 1 month prior to enrollment.
  7. Exhibiting significant suicide risk within the past 12 months, at screening, or at baseline, as evidenced by: a) suicidal ideation with some intent to act but no specific plan (item #4 from the Columbia Suicide Severity Rating Scale57; C-SSRS); b) suicidal ideation with intent to act and a specific plan (item #5 from the C-SSRS); c) suicide attempt or non-suicidal self-injury requiring medical attention in the past 12 months; or d) self-report of significant suicidal ideation with intent or significant non-suicidal self-injury during screening or baseline clinical interview.
  8. Major depressive episode that is secondary to a medication or a general medical condition, as judged by investigators.
  9. Any other factors, such as major medical conditions, unstable housing or threatening life circumstances, erratic behavior, etc. that are judged by the investigators to be a significant barrier to participation in the study protocol and/or to establishing therapeutic rapport necessary for safe administration of psilocybin.
  10. Prior past-year ingestion of a serotonergic psychedelic, e.g., psilocybin, LSD, mescaline, dimethyltryptamine, etc. or more than 5 lifetime ingestions of a serotonergic psychedelic on separate occasions.
  11. Participant unwillingness to not ingest or use additional serotonergic psychedelics outside the context of study procedures for the duration of the study follow-up period (12 months).
  12. Ferrous metal, metallic implants, or implanted medical devices that would preclude administration of rTMS and/or participation in MRI procedures, including but not limited to: cochlear implants, implanted brain stimulators, aneurysm clips.
  13. Past history of seizures or epilepsy (rTMS risk).
  14. Neurological disorder, including epilepsy, stroke, or history of brain surgery.
  15. Past penetrating brain injury or any head injury resulting in a loss of consciousness for 30 minutes or more or post-concussive symptoms for more than seven days following a head injury.
  16. Head injury in the past two months, regardless of severity.
  17. Currently pregnant and/or nursing or about to become pregnant. A positive urine pregnancy test at screening and/or baseline will lead to participant exclusion from the study.
  18. Engagement in sexual intercourse which could result in pregnancy without use of a highly effective method throughout participation in the study and for at least three months after COMP360 (psilocybin) administration.
  19. Severe claustrophobia (prohibiting MRI acquisition).
  20. Uncontrolled hypertension (resting blood pressure > 140/90 mm hg).
  21. Uncontrolled thyroid disease as indicated by unstable thyroid hormone dosage \< 3 months prior to screening, or abnormal and thyroxine (FT4) levels (a free FT4 measurement will be conducted for all participants with an out-of-range thyroid-stimulating hormone [TSH] value irrespective of thyroid history).
  22. Lifetime history of cardiomyopathy, stroke, heart disease, heart attack, tachycardia, elongated -interval corrected by Friderichia (> 450ms for men and > 470ms for women); clinically significant cardiac arrhythmia within 1 year of study entry; and/or abnormal on study entry.
  23. Type I diabetes mellitus or uncontrolled Type II diabetes mellitus (defined by > 8% at screening) or a history of diabetic ketoacidosis, hyperglycemic coma, or severe hypoglycemia with loss of consciousness (\< 3 months prior to signing of consent form).
  24. Positive urine drug screening for drugs of abuse at screening and/or baseline will trigger a review with participant and assessment for eligibility based on pattern of use and willingness to abstain in conjunction with medical monitor and investigative team.
  25. Clinically-significant results from physical examination, blood test, urine test, vital signs, or ECG at screening and/or baseline.
  26. Current enrollment in another interventional study or participation within such a study within 6 months of screening.
  27. Self-reported to psilocybin or another serotonergic psychedelic.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Full dose COMP360 with active aiTBS rTMS

    25mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.

    Drug: Psilocybin · Device: Accelerated intermittent theta burst (aiTBS) rTMS treatment

  • Active comparator
    Full dose COMP360 with sham aiTBS rTMS

    25mg of COMP360 with sham iTBS delivered over 10 sessions daily for 5 consecutive days.

    Drug: Psilocybin · Device: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment

  • Active comparator
    Low dose comparator with active aiTBS rTMS

    1mg of COMP360 with the active accelerated intermittent theta burst (aiTBS) rTMS treatment known as Stanford Neuromodulation Therapy (SNT) and/or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) delivered over 10 sessions daily for 5 consecutive days.

    Device: Accelerated intermittent theta burst (aiTBS) rTMS treatment · Drug: Low-dose psilocybin

  • Sham comparator
    Low dose comparator with sham aiTBS rTMS

    1mg of COMP360 with with sham iTBS delivered over 10 sessions daily for 5 consecutive days.

    Drug: Low-dose psilocybin · Device: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment

Interventions

  • A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).

    Also known as: COMP360

  • DeviceAccelerated intermittent theta burst (aiTBS) rTMS treatment

    A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.

    Also known as: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Stanford Neuromodulation Therapy (SNT)

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).

    Also known as: low-dose COMP360

  • DeviceSham Accelerated intermittent theta burst (aiTBS) rTMS treatment

    The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.

    Also known as: Sham Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), Sham Stanford Neuromodulation Therapy (SNT)

06

What researchers measure

Primary outcomes

  1. Montgomery Asberg Depression Rating Scale (MADRS)

    A ten-item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Scoring ranging from 0 to 60, with higher scores indicating greater depressive symptomology.

    Time frame: 12 months

  2. fMRI task-evoked brain activation

    A method used in functional magnetic resonance imaging (fMRI) to observe different areas of the brain or other organs, which are found to be active at any given time.

    Time frame: At both 1 week and 2 weeks

  3. fMRI resting state

    A method aimed at examining intrinsic networks in the brain while no task is performed (rest) in order to estimate correlations between brain regions.

    Time frame: At both 1 week and 2 weeks

  4. EEG functional connectivity change

    A method aimed at examining intrinsic networks in the brain to estimate correlations between brain regions.

    Time frame: At both 1 week and 2 weeks

Secondary outcomes

  1. Snaith Hamilton Pleasure Scale (SHAPS)

    A self-report measure of anhedonia. Scoring range from 0 to 14, with lower scores indicating less anhedonia.

    Time frame: 12 months

  2. Quick Inventory of Depressive Symptom Self-Report (QIDS-SR)

    A self report measure of depressive symptoms. Scores range from 0 to 48, with lower scores indicating less symptoms of depression.

    Time frame: 12 months

  3. World Health Organization Quality of Life Inventory-Brief subscale (WHO-QL-Brief)

    A self-report measure of quality of life with four subscales: Physical Health, Psychological Health, Social Relationships, and Environment. Scores for each range from 4-20, with higher scores indicating better quality of life.

    Time frame: 12 months

  4. Beck Depression Inventory II (BDI II)

    A self-report measure of positive and negative affect. There are scores for Positive Affect and Negative Affect, each of which is scored from 10-50. Higher scores indicate more of that particular type of affect.

    Time frame: 12 months

  5. Anxiety Sensitivity Index 3 (ASI-3)

    A self-report measure of anxiety sensitivity. Scores range from 0 to 72, with lower scores indicating less anxiety sensitivity.

    Time frame: 12 months

  6. Beck Anxiety Inventory (BAI)

    A self report measure of anxiety symptoms. Scores range from 0 to 63, with lower scores indicating less anxiety.

    Time frame: 12 months

  7. Mood and Anxiety Symptom Questionnaire 30 item Anhedonic Depression subscale (MASQ-30)

    A subscale measure of anhedonic depressive symptoms. Scores range from 10-50, with lower scores indicating less anhedonic depression.

    Time frame: 12 months

  8. Mood and Anxiety Symptom Questionnaire 30 item Anxious Arousal subscale (MASQ-30)

    A subscale measure of anxious arousal symptoms. Scores range from 10-50, with lower scores indicating less anxious arousal.

    Time frame: 12 months

  9. Physicians Health Questionnaire 9 (PHQ-9)

    A self-report screener of major depression. Scores range from 0 to 27, with lower scores indicating fewer symptoms of depression.

    Time frame: 12 months

  10. Generalized Anxiety Disorder 7 (GAD-7)

    A self-report screener of generalized anxiety disorder. Scores range from 0 to 21, with lower scores indicating less symptoms of generalized anxiety.

    Time frame: 12 months

  11. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Clinician-administered measure of suicidal ideation. Scores range from 0 to 25, with higher scores indicating more severe suicidal ideation.

    Time frame: 12 months

  12. Anger Attacks Questionnaire (AAQ)

    Self-report measure of anger outbursts. Scores range from 5-25, with higher scores indicating more severe expressions of anger.

    Time frame: 12 months

  13. Brief Psychiatric Rating Scale (BPRS)

    A tool clinicians or researchers use to measure psychiatric symptoms such as anxiety, depression, and psychoses. Scores range from 18 to 126, with lower scores indicating less severe psychiatric symptoms a score of 18 meaning no symptoms present.

    Time frame: 2 weeks

  14. Sheehan Disability Scale (SDS)

    Self-report screener that measures impairment in functioning and generates 4 scores: a work disability score, a social life disability score, a family life disability score and a total score. To get a total score add up the 3 individual scores (work: social life: family life). The maximum possible score is 30, meaning more severe impairment from experienced disability.

    Time frame: 12 months

  15. Positive and Negative Affect Scale Short Form (PANAS-SF)

    Self-Report scale that consists of different words that describe feelings and emotions to measure positive and negative affect. Scores are divided into two categories: 1) can range from 10-50 with higher scores representing higher levels of positive affect and 2) can range from 10-50 with lower scores representing lower levels of negative affect.

    Time frame: 12 months

  16. Acceptance and Action Questionnaire II (AAQ II)

    Self-report measure that tracks how individuals are applying flexibility skills to their daily lives. 7 item scale with scores ranging from 7-49,with higher scores indicating higher psychological inflexibility, experiential avoidance, and more potential for psychological stress.

    Time frame: 12 months

  17. NEO Five Factor Inventory (NEO-FFI)

    Self-report measure that assesses subjects for five domains of normal personality: neuroticism, extraversion, conscientiousness, agreeableness, and openness. Each domain is a 12-item scale with scores ranging from 12-60 where the combined scores create a personality profile.

    Time frame: 12 months

  18. Emotion Regulation Questionnaire (ERQ)

    A 10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Assesses cognitive reappraisal (6 items) and expressive suppression (4 items) on a 7-point Likert-type response scale, with higher scores on each scale indicate greater use of the corresponding emotional regulation strategy. Min 10 - max 70.

    Time frame: 12 months

  19. UCLA Loneliness Scale 3 (UCLA-LS-3)

    Clinician administered scale that comprises 3 questions that measure three dimensions of loneliness: relational connectedness, social connectedness, and self-perceived isolation. Each item is rated on a 3-point scale for a range of 3-9, with higher scores meaning more intense feelings of the 3 dimensions of loneliness.

    Time frame: 12 months

  20. Freiberg Mindfulness Inventory (FMI)

    Self-report questionnaire for measuring mindfulness. A 14-item scale with scores 14-56 with higher scores meaning a higher degree of mindfulness.

    Time frame: 12 months

  21. Discontinuation Emergent Signs and Symptoms Scale

    Self-report measure of 43-items that assess changes in symptomology when starting a new treatment. This measures does not correlate scores to an outcome but is used to assess the development of a new symptom or the worsening of an already existing one.

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — If participants chose to, they can be included in the Department of Psychiatry's Registry (Protocol 2020-04-0046). Participants may elect to be part of this registry, but this is not required as part of the participation in the current study. No other plans for sharing data outside of a research related inquiry for research purposes is expected. The registry informed consent will be provided to the participant if interested and consent will be obtained per procedures outlined in the registry protocol. De-identified data may be shared with future researchers for scientific purposes. If our lab shares biospecimens with future researchers, it will only be de-identified data. In this case, it will be shared in the form of an aggregated database with no PHI or PII included.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2029, 59 months after the start.

Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 15, 2023
StartActual
Jan 10, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2030
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06132178
Responsible party
Greg Fonzo (Assistant Professor, University of Texas at Austin) — Principal investigator
First posted
Nov 15, 2023
Start date
Jan 10, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 26, 2025

Study contacts

Lauren K Enten, B.S.A.
Contact
psychedelics@utexas.edu
512-495-5856
Gregory A Fonzo, Ph.D.
Contact
fonzolab@austin.utexas.edu
Gregory A Fonzo, Ph.D.
principal investigator · The University of Texas at Austin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion